Affinity Asset Advisors, LLC has filed its 13F form on February 13, 2025 for Q4 2024 where it was disclosed a total value porftolio of $560 Million distributed in 85 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Xenon Pharmaceuticals Inc. with a value of $45.5M, Arcellx, Inc. with a value of $32.4M, Alkermes Plc. with a value of $31.6M, Teva Pharmaceutical Industries LTD with a value of $30.9M, and Verona Pharma PLC with a value of $30.7M.

Examining the 13F form we can see an decrease of $19.2M in the current position value, from $579M to 560M.

Affinity Asset Advisors, LLC is based out at New York, NY

Below you can find more details about Affinity Asset Advisors, LLC portfolio as well as his latest detailed transactions.

Portfolio value $560 Million
Healthcare: $492 Million
ETFs: $67.5 Million

Stock Holdings Table Companies Only

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History

Summary

  • Portfolio
  • No. of Stocks 85
  • Current Value $560 Million
  • Prior Value $579 Million
  • Filing
  • Period Q4 2024
  • Filing Date February 13, 2025
  • Form Type 13F-HR
  • Activity in Q4 2024
  • New Purchases 15 stocks
  • Additional Purchases 24 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 20 stocks
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.